StockGuide AI - assistant for market research

Analysts UBS lowered Zealand Pharma (ZEAL) price target to 540 Danish kroner amid concerns over survodutide’s tolerability

06/18/2026, 10:36 PM business rating_drop Analysts: analysts, UBS biotech

Zealand Pharma's stock has faced significant declines following disappointing data on its weight loss drug survodutide, leading analysts to reduce sales forecasts and shift focus to its other drug, petrelintide, which may offer better prospects in the obesity market.

JPMorgan Analysts Highlight Reopening Biotech IPO Market Amid Continued Big Pharma M&A Activity

06/15/2026, 10:36 PM business review Analysts: analysts, JPMorgan biotech healthcare

The biotech sector is experiencing a resurgence in public market activity, but many leading companies may prefer acquisition by larger pharmaceutical firms over pursuing initial public offerings (IPOs). This trend reflects a selective investment climate and a strategic shift in how biotech firms approach growth and funding.

Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026

06/03/2026, 11:30 PM business review biotech healthcare

The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.

Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial

06/02/2026, 12:31 AM stock_drop biotech

Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.

Innovent Biologics (1801.HK) Shares Surge 10% Following $10.5 Billion Partnership with Pfizer

05/28/2026, 08:32 PM announcement biotech

Innovent Biologics has entered a strategic partnership with Pfizer, which is expected to enhance its oncology drug development capabilities.

Analysts BTIG initiate coverage of Absci Corporation (ABSI) with a buy rating and $9 price target, citing potential for ABS-201 in hair loss treatment

05/28/2026, 07:33 AM investing rating_growth Analysts: analysts, BTIG biotech

Absci Corporation's innovative hair loss treatment, ABS-201, has garnered a buy rating from BTIG, with a projected peak sales potential of $2.2 billion, indicating significant market opportunity in a largely underserved sector.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 07:32 AM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.

U.S. Promotes AI Technology in Asia Following Trump-Xi Meeting

05/22/2026, 05:34 AM business announcement ai biotech

The U.S. is intensifying efforts to promote American technology, particularly in artificial intelligence, in Asia amid competition with China, which is developing its own alternatives. This strategic push follows a recent meeting between Presidents Trump and Xi, highlighting the importance of U.S. tech in the region.

Biotech and Real Estate Sectors Show Mixed Performance Ahead of Key Oncology Meeting

05/21/2026, 04:32 PM investing review biotech real_estate

The upcoming meeting of the American Society of Clinical Oncology is poised to influence biotech stocks, which have shown significant gains over the past year despite recent fluctuations. Additionally, a substantial government investment in quantum computing has sparked notable stock increases in that sector.

Topic: biotech